Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Sell
6
RARE Quote, Financials, Valuation and Earnings
Last price:
$23.40
Seasonality move
:
-0.15%
Day range:
$22.49 - $22.98
52-week range:
$18.41 - $46.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.52x
P/B ratio:
239.64x
Volume:
3M
Avg. volume:
3.3M
1-year change:
-44.89%
Market cap:
$2.2B
Revenue:
$560.2M
EPS (TTM):
-$5.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$198.8M | -$1.12 | 23.45% | -9.57% | $63.90 |
|
CORT
Corcept Therapeutics, Inc.
|
$246.1M | $0.24 | 27.74% | -71.78% | $91.00 |
|
CRMD
CorMedix, Inc.
|
$128.3M | $0.80 | 195.3% | 90.44% | $16.86 |
|
FOLD
Amicus Therapeutics, Inc.
|
$179.8M | $0.16 | 20.08% | 234.42% | $14.83 |
|
GERN
Geron Corp.
|
$50.9M | -$0.05 | 32.79% | -16.11% | $3.60 |
|
JNJ
Johnson & Johnson
|
$24.2B | $2.46 | 6.17% | -39.04% | $212.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$22.75 | $63.90 | $2.2B | -- | $0.00 | 0% | 3.52x |
|
CORT
Corcept Therapeutics, Inc.
|
$36.31 | $91.00 | $3.8B | 41.49x | $0.00 | 0% | 5.86x |
|
CRMD
CorMedix, Inc.
|
$7.33 | $16.86 | $577.5M | 3.57x | $0.00 | 0% | 2.47x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.35 | $14.83 | $4.4B | -- | $0.00 | 0% | 7.34x |
|
GERN
Geron Corp.
|
$1.34 | $3.60 | $855.4M | -- | $0.00 | 0% | 4.86x |
|
JNJ
Johnson & Johnson
|
$218.01 | $212.00 | $525.3B | 19.74x | $1.30 | 2.36% | 5.62x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
98.95% | 0.967 | 29.68% | 1.61x |
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.281 | 0.07% | 2.85x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.954 | 0.48% | 1.60x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.323 | 18.22% | 1.91x |
|
GERN
Geron Corp.
|
50.25% | 1.450 | 28.73% | 4.76x |
|
JNJ
Johnson & Johnson
|
36.62% | -0.032 | -- | 0.71x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
RARE
Ultragenyx Pharmaceutical, Inc.
|
$123.3M | -$170.9M | -53.69% | -307.83% | -106.85% | -$92.7M |
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
GERN
Geron Corp.
|
$45.9M | -$13.9M | -16.45% | -29.65% | -29.41% | -$13.5M |
|
JNJ
Johnson & Johnson
|
$17.8B | $5.6B | 21.7% | 33.27% | 22.76% | $8B |
Ultragenyx Pharmaceutical, Inc. vs. Competitors
-
Which has Higher Returns RARE or CORT?
Corcept Therapeutics, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 9.32%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Corcept Therapeutics, Inc.'s return on equity of 16%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M -
What do Analysts Say About RARE or CORT?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $63.90, signalling upside risk potential of 180.88%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $91.00 which suggests that it could grow by 150.62%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Corcept Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 CORTCorcept Therapeutics, Inc.3 1 1 -
Is RARE or CORT More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.155, which suggesting that the stock is 84.518% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.232, suggesting its less volatile than the S&P 500 by 76.804%.
-
Which is a Better Dividend Stock RARE or CORT?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RARE or CORT?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 41.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.52x versus 5.86x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.3.52x -- $159.9M -$180.4M CORTCorcept Therapeutics, Inc.5.86x 41.49x $207.6M $19.4M
-
Which has Higher Returns RARE or CRMD?
CorMedix, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 49.9%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About RARE or CRMD?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $63.90, signalling upside risk potential of 180.88%. On the other hand CorMedix, Inc. has an analysts' consensus of $16.86 which suggests that it could grow by 129.98%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than CorMedix, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 CRMDCorMedix, Inc.4 0 0 -
Is RARE or CRMD More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.155, which suggesting that the stock is 84.518% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.358, suggesting its more volatile than the S&P 500 by 35.753%.
-
Which is a Better Dividend Stock RARE or CRMD?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RARE or CRMD?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.52x versus 2.47x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.3.52x -- $159.9M -$180.4M CRMDCorMedix, Inc.2.47x 3.57x $104.3M $108.6M
-
Which has Higher Returns RARE or FOLD?
Amicus Therapeutics, Inc. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 10.24%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About RARE or FOLD?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $63.90, signalling upside risk potential of 180.88%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.83 which suggests that it could grow by 3.37%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 FOLDAmicus Therapeutics, Inc.2 5 0 -
Is RARE or FOLD More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.155, which suggesting that the stock is 84.518% less volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.417, suggesting its less volatile than the S&P 500 by 58.311%.
-
Which is a Better Dividend Stock RARE or FOLD?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RARE or FOLD?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.52x versus 7.34x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.3.52x -- $159.9M -$180.4M FOLDAmicus Therapeutics, Inc.7.34x -- $169.1M $17.3M
-
Which has Higher Returns RARE or GERN?
Geron Corp. has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of -39.02%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Geron Corp.'s return on equity of -29.65%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M GERNGeron Corp.97.13% -$0.03 $500M -
What do Analysts Say About RARE or GERN?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $63.90, signalling upside risk potential of 180.88%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 168.66%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Geron Corp., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Geron Corp..
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 GERNGeron Corp.3 1 1 -
Is RARE or GERN More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.155, which suggesting that the stock is 84.518% less volatile than S&P 500. In comparison Geron Corp. has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.567%.
-
Which is a Better Dividend Stock RARE or GERN?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios RARE or GERN?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are larger than Geron Corp. quarterly revenues of $47.2M. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Geron Corp.'s net income of -$18.4M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.52x versus 4.86x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.3.52x -- $159.9M -$180.4M GERNGeron Corp.4.86x -- $47.2M -$18.4M
-
Which has Higher Returns RARE or JNJ?
Johnson & Johnson has a net margin of -112.81% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 20.83%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83% beat Johnson & Johnson's return on equity of 33.27%.
Company Gross Margin Earnings Per Share Invested Capital RAREUltragenyx Pharmaceutical, Inc.77.12% -$1.81 $879.3M JNJJohnson & Johnson72.39% $2.10 $125.1B -
What do Analysts Say About RARE or JNJ?
Ultragenyx Pharmaceutical, Inc. has a consensus price target of $63.90, signalling upside risk potential of 180.88%. On the other hand Johnson & Johnson has an analysts' consensus of $212.00 which suggests that it could fall by -2.76%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Johnson & Johnson, analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings RAREUltragenyx Pharmaceutical, Inc.15 1 0 JNJJohnson & Johnson9 11 0 -
Is RARE or JNJ More Risky?
Ultragenyx Pharmaceutical, Inc. has a beta of 0.155, which suggesting that the stock is 84.518% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.
-
Which is a Better Dividend Stock RARE or JNJ?
Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.36% to investors and pays a quarterly dividend of $1.30 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios RARE or JNJ?
Ultragenyx Pharmaceutical, Inc. quarterly revenues are $159.9M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M is lower than Johnson & Johnson's net income of $5.1B. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 19.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.52x versus 5.62x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income RAREUltragenyx Pharmaceutical, Inc.3.52x -- $159.9M -$180.4M JNJJohnson & Johnson5.62x 19.74x $24.6B $5.1B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Sell
47
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Sell
27
RGC alert for Jan 22
Regencell Bioscience Holdings Ltd. [RGC] is up 40.39% over the past day.
Buy
62
BNR alert for Jan 22
Burning Rock Biotech Ltd. [BNR] is up 33.29% over the past day.
Buy
71
HYMC alert for Jan 22
Hycroft Mining Holding Corp. [HYMC] is up 17.39% over the past day.
